3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma CMPS

COMPASS Pathways Plc American Depository Shares

CMPS NASDAQ US20451W1018 Biotech & Pharma

Stock factsheet

TickerCMPS
ExchangeNASDAQ
ISINUS20451W1018
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 1,53 Mrd. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

COMPASS Pathways is a British biopharmaceutical company developing psilocybin-based therapies for mental health conditions. Its lead candidate, COMP360, is being investigated in clinical trials for the treatment of treatment-resistant depression. The company is listed on NASDAQ via American Depositary Shares.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
COMPASS Pathways Plc American Depository SharesCMPS NASDAQ1,53 Mrd. USD
BioLife Solutions, Inc. BLFSNASDAQ 1,53 Mrd. USD
First Tracks Biotherapeutics, Inc. TRAXNASDAQ 1,54 Mrd. USD
Innoviva, Inc. INVANASDAQ 1,55 Mrd. USD
Septerna, Inc. SEPNNASDAQ 1,55 Mrd. USD
Xencor, Inc. XNCRNASDAQ 1,50 Mrd. USD
Forte Biosciences, Inc. FBRXNASDAQ 1,57 Mrd. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.